Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Immunocore Holdings reported Q2 2026 KIMMTRAK net product revenue of $115.9 million, up 18% year over year, with sales of $74.9 million in the US, $34.1 million in Europe and $6.9 million in international markets. Net loss narrowed to $0.8 million in the quarter, and the company generated $12.2 million net income for the first half of 2026.
R&D spending was $73.9 million in Q2 as three Phase 3 studies advanced. Cash, cash equivalents and marketable securities totaled $880.2 million as of June 30, 2026, compared with $864.2 million at year-end 2025; the company expects to pay about $120 million in sales-related rebate accruals in the second half of 2026.
Five-year data from the Phase 3 KIMMTRAK trial in metastatic uveal melanoma showed overall survival of 16% at five years versus 8% for control, with median overall survival of 21.6 vs 16.9 months. Enrollment is nearing completion in the Phase 3 TEBE-AM trial in previously treated cutaneous melanoma, the PRISM-MEL-301 Phase 3 trial is enrolling first-line cutaneous melanoma patients, and the pipeline also includes PRAME-targeting brenetafusp studies, an HIV program (IMC‑M113V) and autoimmune candidates such as IMC‑S118AI.
Immunocore Holdings plc director Peter John Ratcliffe received a new stock option grant. On May 27, 2026, he was granted options over 27,492 ordinary shares at an exercise price of $28.52 per share, with no cash paid for the grant itself.
The options expire on May 26, 2036 and represent his entire reported option position of 27,492 options following this transaction. According to the terms, the award will vest at the earlier of May 27, 2027 or the day immediately prior to Immunocore’s next annual general meeting, provided he continues in service through the vesting date.
Immunocore Holdings plc reported that director Kristine Peterson received a stock option grant covering 27,492 ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036. The award vests at the earlier of May 27, 2027 or the day immediately prior to the company’s next annual general meeting, contingent on her continued service. This is a compensation-related award rather than an open-market share purchase or sale.
Immunocore Holdings plc director William Pao received a new stock option grant. The award covers 27,492 options to buy Ordinary Shares at an exercise price of $28.52 per share, expiring on May 26, 2036.
The options vest at the earlier of May 27, 2027, or the day immediately before Immunocore’s next annual general meeting, as long as Pao remains in continuous service through the vesting date. Following this grant, he holds 27,492 share options directly.
Immunocore Holdings plc director Siddharth Kaul received a grant of share options for 27,492 ordinary shares. The options carry an exercise price of $28.52 per share and expire on May 26, 2036, providing long-term equity-based compensation.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, as long as Kaul remains in continuous service until that vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Immunocore Holdings plc director Roy Steven Herbst received a grant of 27,492 share options to buy ordinary shares. The options have an exercise price of $28.52 per share and expire on May 26, 2036, according to the Form 4.
The award vests at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service through the vesting date. After this grant, the filing shows 27,492 derivative securities held directly.
Immunocore Holdings plc director John Irving Bell received a grant of 27,492 share options. Each option gives the right to buy one ordinary share at an exercise price of $28.52 and expires on May 26, 2036. According to the terms, the options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service until that vesting date. Following this award, he holds 27,492 derivative securities linked to ordinary shares.
Immunocore Holdings plc reported the results of its 2026 Annual General Meeting of Shareholders. All ten resolutions proposed at the meeting were approved on a poll.
Shareholders re-appointed directors Siddharth Kaul, William Pao, M.D., Ph.D., and Kristine Peterson. They also approved, on an advisory basis, the compensation of named executive officers and the directors’ remuneration report for the year ended December 31, 2025.
Deloitte LLP was ratified as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026 and re-appointed as U.K. statutory auditors, with the audit committee authorized to set their remuneration. Shareholders received and adopted the 2025 U.K. statutory annual accounts and reports and authorized the Company to make political donations or incur political expenditure.
Immunocore Holdings plc (IMCR) lists a notice by affiliate David Berman for a proposed sale of 69,271 ADRs, with an aggregate market value of $2,042,147.94 and an approximate sale date of May 22, 2026. The transaction is described as a same-day cashless exercise and sale. J.P. Morgan Securities LLC, Workplace Solutions, signed as agent and attorney in fact for David Berman.
Immunocore Holdings Plc disclosed a proposed sale of 65,000 ADRs via a Same Day Cashless Exercise and Sale scheduled on 05/21/2026 with expected settlement on 05/22/2026. The filing also lists prior sales by David Berman of 11,832 ADRs on 03/11/2026 and 25,000 ADRs on 04/08/2026, with reported gross proceeds of $385,330.11 and $798,510.57, respectively.